What Haemaccel (Gelatin) Treats: Main Uses and Benefits

Haemaccel is commonly used as a supportive volume expander to address hypovolemic shock, a severe condition where dangerously low circulating fluid volume is associated with severe physiological strain. The medication is relevant in contexts marked by increased discomfort and is applied in clinical settings that involve acute or unstable symptom patterns.

Its therapeutic role is supportive assistance in the restoration of circulating fluid volume in cases of blood loss, plasma loss, or peri-operative fluid deficiency. This process helps the patient in managing functional stability and supports general well-being during symptomatic phases by generally helping to address symptoms of circulatory collapse and low blood pressure.

The medication is commonly used for managing symptomatic patterns arising from acute conditions like severe trauma, major surgery, extensive burns, and specialized procedures such as extracorporeal circulation. In these situations, Haemaccel is applied when short-term symptomatic assistance with fluid replacement is needed. This temporary volume expansion offers symptomatic relief that helps patients cope more steadily with the physical strain of severe, sudden fluid depletion and may assist with maintaining functional stability during critical phases.

Quick Fact: Relief for Hypovolemic Shock	Domain	Benefit
Symptom Cluster	Symptoms related to systemic imbalance and low blood pressure.
Practical Support	Contributes to easing the overall symptom load by supporting circulation.
Severity Relevance	Used in situations involving heightened physiological stress and acute episodes.

Who can and cannot use Haemaccel (Gelatin)? Official Eligibility Information

The regulatory profile for Haemaccel defines eligibility through both absolute contraindications and conditional restrictions.

Populations for Whom Use is Contraindicated

Use is formally contraindicated in individuals with a known hypersensitivity to Polygeline or its constituents, those with existing anaphylactoid reactions, and when used for correcting drug-induced hypotensive effects.

Populations Requiring Restricted or Conditional Use

Regulatory documents indicate the medicine is for restricted extent only and requires special precautions in populations where an increase in circulating volume could pose a special risk. This conditional use applies to patients with congestive heart failure, pulmonary oedema, hypertension, oesophageal varices, and renal or post-renal anuria.

Special precautions are also mandated for individuals with haemorrhagic diathesis (bleeding tendency) and those at an increased risk of histamine release.

Age and Physiological Status Eligibility

The official label does not list specific pediatric or geriatric contraindications. For pregnancy, use may be considered if blood is not available for plasma volume replacement during procedures such as obstetric hemorrhage.

The official interaction profile for Haemaccel (Polygeline) is defined by pharmacodynamic effects and specific procedural constraints, according to government regulatory documentation.

Documented Pharmacodynamic Interactions

Co-administration with cardiac glycosides (such as Digoxin or Digitoxin) requires caution due to the specific composition of Haemaccel. The solution contains calcium ions, which can exert a synergistic pharmacodynamic effect leading to the risk of enhanced digitalis-induced toxicity.

Additionally, regulatory labels indicate a potential for cumulative effects when Haemaccel is administered alongside other histamine-releasing drugs. This category includes certain anaesthetics, analgesics, and muscle relaxants. The combination may increase the overall risk of anaphylactoid reactions.

Procedural Incompatibilities and Restrictions

The most stringent interaction constraint is an in-vitro incompatibility related to mixing. Haemaccel must not be mixed directly with citrated blood (such as stored blood product) during infusion. The calcium ions in the Haemaccel solution can cause the citrated blood to clot. If citrated blood is administered immediately before or after Haemaccel, the infusion set must be subjected to an adequate flushing procedure to prevent this physical incompatibility. Furthermore, Haemaccel is subject to a general restriction: it should not be mixed with other medicinal products unless official compatibility studies confirm the safety of the combination. No interactions with food, alcohol, or herbal products are documented in the regulatory labeling.

Haemaccel is a colloid solution containing Polygeline (a modified gelatin polypeptide) and electrolytes that exerts its primary action through physiochemical principles influencing circulatory and cellular functions.

Intravascular Volume Expansion and Oncotic Effects

This mechanism involves the high-molecular-weight Polygeline molecules, which remain confined to the vascular space following infusion. These molecules generate a sustained oncotic pressure that establishes an osmotic pressure differential. This differential drives the net movement of interstitial fluid into the vasculature, resulting in an increase of circulating blood volume.

Electrolyte Exchange and Cellular Gradients

The mineral salts included—primarily sodium, potassium, and calcium chlorides—facilitate the delivery of specific ions. These ions contribute to the maintenance of transmembrane electrochemical gradients, which influences nerve signal conduction, muscle cell excitation, and systemic osmotic regulation.

Coagulation Pathway Influence

This component relates to the impact of the calcium ions ( Ca^2+). The presence of Ca^2+ provides a necessary cofactor for the activation of multiple prothrombin factors within the intrinsic and extrinsic coagulation pathways. Furthermore, the solution's physiochemical properties, including isotonicity and near-plasma pH, ensure a suitable environment for erythrocyte and leukocyte viability.

Haemaccel is administered exclusively as an intravenous infusion (IV drip) in a controlled clinical setting, with the total volume and rate dictated by the patient's acute need for plasma volume restoration. The concentration of the solution used is 3.5%, w/v Polygeline.

Labeled Dosing Regimens

The volume of Haemaccel administered is intended to be approximately equal to the estimated blood or fluid loss. Initial dosing for hypovolemic shock typically begins with 500 ml to 1,000 ml infused intravenously.

For Blood Loss Management:

• Losses up to 1,500 ml may be replaced entirely by Haemaccel.
• For moderate losses (1,500 ml to 4,000 ml), replacement should be with equal volumes of Haemaccel and blood (given separately).
• The maximum total volume administered is ultimately constrained by the rule that the patient's Haematocrit should not be allowed to fall below 25%.

Administration Conditions and Constraints

The rate of infusion is determined by the patient's condition. Normally, 500 ml of the solution is infused in not less than 60 minutes, but the solution can be infused rapidly in emergency situations.

Before use, the solution should be warmed to body temperature if possible, though infusion at ambient temperature is allowed in emergencies. Haemaccel may be mixed with certain other IV solutions; however, citrated blood must NOT be mixed with Haemaccel in the same line due to the presence of calcium ions. If citrated blood is required, it must be administered before or after Haemaccel, ensuring the infusion set is adequately flushed in between.

Research Evidence / Overview of Studies for Haemaccel (Gelatin)

Evidence for Volume Replacement in Hypovolemic Shock

Research has explored the use of this solution as a plasma volume substitute in the context of hypovolemic shock, a serious condition characterized by sudden fluid loss. Studies include Randomized Controlled Trials (RCTs) and systematic reviews conducted in critically ill adults (trauma, surgery, sepsis). Researchers monitored immediate physiological changes and major patient endpoints like survival rates and the development of acute kidney injury. Findings related to major clinical outcomes have varied across studies, and the follow-up durations were often limited to only a few days or weeks.

---

Evidence for Fluid Management During Major Surgery

The solution was evaluated in studies involving both adults and children undergoing planned surgical procedures. These trials were designed to examine the solution's influence on measured circulation and fluid balance during surgery. The research describes patterns related to measurements of hemodynamic parameters. However, for outcomes related to blood transfusion requirements or significant post-surgical complications, findings were mixed or did not clearly indicate consistent differences when compared to standard non-colloid fluids.

---

Research Context in Severe Sepsis and Septic Shock

The research base specifically examining the use of this solution in patients with severe sepsis or septic shock is more limited. The data often stem from subgroup analyses conducted within larger research projects. The published data concerning potential differences in survival or organ dysfunction when comparing the solution to other fluids in this severely ill context are still emerging and findings were mixed. The certainty remains low because the evidence is often derived from secondary looks at data rather than trials originally designed for this specific patient group.

---

Long-Term Studies and Follow-Up

Across all indications, long-term effects are not fully established. The research focus has been on the immediate physiological responses that occur during the first hours or days after the solution is administered. There is limited information for long-term outcomes regarding sustained patient recovery or possible long-term impacts on organ function.

---

Evidence in Specific Patient Groups

The research has studied the use of this solution in certain groups, including children undergoing surgery and older adults in critical care. However, data for certain groups remain insufficient to establish robust patterns, and the sample sizes were modest in many studies.

---

What Is Still Uncertain About Haemaccel (Gelatin)

A number of research limitations contribute to the uncertainty of the available evidence. Comparative evidence is lacking, meaning that head-to-head data from large, definitive, randomized trials comparing this solution to other options is not available for all indications. In summary, the existing studies provide context but not individual predictions, and the results apply only to the populations studied and the specific, short-term conditions under which they were conducted.

Key Studies & References

1. HPRA Regulatory Document for Haemaccel (Polygeline) - Summary of Product Characteristics (PA1206/001/001)
2. NICE Guideline: Intravenous fluid therapy in adults in hospital (Clinical Guideline 174)

Common questions about Haemaccel (Gelatin) (FAQ)

Q: Is Haemaccel the same as regular edible gelatin?

A: Official information states that Haemaccel is not the same as regular edible gelatin. The active ingredient is Polygeline, which is a chemically modified fluid gelatin derived from bovine collagen. This makes it a specialized pharmaceutical product, distinct from food-grade gelatin.

Q: How quickly does Haemaccel start working after it's administered?

A: As a synthetic plasma volume expander, Haemaccel is designed to act immediately upon infusion to help restore circulating blood volume. Clinical studies report a significant response in vital signs, such as blood pressure, with the effect starting immediately upon infusion.

Q: How long does the volume-expanding effect of Haemaccel last?

A: Official information indicates that the active substance, Polygeline, has a plasma half-life of approximately five hours. The duration of the volume-expanding effect is related to how long the larger molecules of Polygeline are retained within the bloodstream.

Q: Is it normal to feel cold after receiving Haemaccel?

A: Regulatory documents advise that the Haemaccel solution should be warmed to body temperature before it is infused. While not universal, shivering is listed in the official safety profile as an uncommon side effect that may occur during or immediately after the infusion.

Q: Does Haemaccel affect blood clotting?

A: The product label includes a specific procedural constraint that Haemaccel must not be mixed directly with citrated blood (such as stored blood) as this can cause the citrated blood to clot due to the solution's calcium content. For patients, the label also notes that special care should be taken for those with a pre-existing bleeding tendency.

Q: Can receiving Haemaccel affect my lab test results?

A: Official information notes that Haemaccel may cause temporary influences on certain lab tests. For instance, it may briefly cause a slight rise in serum calcium levels and a temporary increase in the erythrocyte sedimentation rate (ESR). Some studies have also observed a brief increase in the protein levels in urine.

Q: Are there any long-term side effects from getting Haemaccel infusions?

A: Available research has primarily focused on the immediate physiological responses in the hours and days following administration. Because of this focus on acute care, there is limited long-term information regarding sustained patient recovery or potential long-term impacts on organ function.

Q: Is Haemaccel safe for use in children?

A: The official product label does not list specific contraindications based on age for children. However, official information indicates that the product should only be administered to children with careful medical supervision.

Q: What happens to Haemaccel in the body after it has done its job?

A: Once the product has achieved volume expansion, the Polygeline molecules are processed into smaller fragments by enzymes in the body. The majority of the substance is then typically excreted via the kidneys within a few days.

Q: Can Haemaccel cause kidney problems?

A: Official documents require special care for patients with pre-existing conditions like severe kidney dysfunction or renal or post-renal anuria (lack of urine production). Clinical studies have monitored for effects on the kidneys.

Q: Why is the infusion speed for Haemaccel sometimes slower or faster?

A: The rate at which the solution is administered is entirely determined by the patient's clinical condition and acute need for volume replacement. While there is a standard minimum infusion time, the solution can be infused rapidly in emergencies to quickly restore a dangerously low blood volume.

Q: What happens if the solution has gelled due to cold temperatures?

A: Haemaccel should be stored below 25 C. If the solution is exposed to very low temperatures and has gelled, it should be warmed up to restore its proper fluid state before being used for infusion.

Q: Does Haemaccel need to be warmed up before infusion?

A: Administration instructions state that the solution should be warmed to body temperature if possible, before infusion. However, in acute life-threatening emergencies, the product label allows it to be infused at ambient temperature when necessitated by an emergency.

Q: Can Haemaccel be used for patients with liver issues?

A: The official product restrictions do not specifically list liver issues. The formal contraindications focus mainly on severe heart, lung, and kidney conditions. Medical professionals typically exercise caution when administering critical care medicine to patients with significant organ dysfunction.

Q: How does Haemaccel specifically help maintain blood pressure?

A: Haemaccel works because the Polygeline molecules remain in the blood vessels, creating a sustained oncotic pressure. This pressure helps draw fluid from the body's tissues back into the circulation, which results in an increase in the overall blood volume necessary to stabilize and maintain blood pressure.

Q: Is Haemaccel associated with any electrolyte imbalances?

A: The solution is balanced and includes key electrolytes like sodium, potassium, and calcium to aid in physiological compatibility. However, the presence of calcium ions can cause a transient elevation of serum calcium levels, particularly during rapid infusion, which is closely monitored by healthcare staff.

Q: Can patients who are vegetarian or vegan receive Haemaccel?

A: The active ingredient, Polygeline, is a modified fluid gelatin derived from bovine collagen, which is an animal source. Patients who have personal dietary or ethical restrictions should be aware of this origin.

Q: Why is my urine output monitored closely after getting Haemaccel?

A: Close monitoring of urine output helps doctors confirm that the body is responding appropriately to the infusion. Studies indicate that restoring circulatory volume often results in an increase in urine flow (diuresis). This measurement helps guide treatment decisions.

Q: Is Haemaccel sometimes used during childbirth?

A: Official texts indicate that Haemaccel may be considered for severe bleeding (hemorrhage) around the time of childbirth or during gynecological procedures, particularly if compatible blood products are not immediately available for plasma volume replacement.

Q: Are there any religious concerns about receiving Haemaccel?

A: The active substance, Polygeline, is derived from bovine collagen (an animal source). This information is provided so patients can discuss this origin with their physician relative to any personal religious or ethical concerns.

Q: Does Haemaccel contain sugar or calories?

A: According to the official composition, the solution contains Polygeline and various mineral salts dissolved in water. The product label does not list sugar or calories as constituents.

Q: Can Haemaccel be given to older patients (geriatric population)?

A: The official label does not list specific contraindications for older patients. However, careful medical supervision is typically required due to the possibility of co-existing conditions which may affect the patient's response to volume expansion.

Q: Does Haemaccel affect the oxygen-carrying capacity of the blood?

A: Haemaccel is a volume expander but does not carry oxygen itself. To prevent excessive blood dilution, regulatory documents limit the total volume administered to ensure the patient's Haematocrit (the percentage of red blood cells) does not fall below 25%.

Q: Why is my blood pressure checked frequently while receiving Haemaccel?

A: Blood pressure is monitored closely because Haemaccel is designed to stabilize circulation. However, the official safety profile lists hypotension (low blood pressure) as an uncommon side effect. Frequent checks are necessary to monitor the infusion's effects and to confirm that the patient is responding appropriately to the infusion.

Official Storage and Disposal Requirements

Haemaccel solution for infusion must be stored at a temperature below 25 C, and no refrigeration is required. The product has an unopened shelf life of 2 years. If the solution has gelled due to exposure to very low temperatures, it must be warmed before use to restore its proper fluidity.

Due to the lack of preservatives, the solution is strictly for single use only. Any unused fluid must be discarded immediately once the bottle has been opened. The container must not be used if the seal has been broken or if the contents appear cloudy. Unused or expired Haemaccel should be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Additionally, the medicine must be kept out of the sight and reach of children.